DACARBAZINE, CISPLATIN AND CARMUSTINE, WITH OR WITHOUT TAMOXIFEN, FOR METASTATIC MELANOMA - 5-YEAR FOLLOW-UP

被引：59

作者：

LATTANZI, SC ^{[1
]}

TOSTESON, T ^{[1
]}

CHERTOFF, J ^{[1
]}

MAURER, LH ^{[1
]}

ODONNELL, J ^{[1
]}

LEMARBRE, PJ ^{[1
]}

MOTT, L ^{[1
]}

DELPRETE, SA ^{[1
]}

FORCIER, RJ ^{[1
]}

ERNSTOFF, MS ^{[1
]}

机构：

[1] DARTMOUTH HITCHCOCK MED CTR,NORRIS COTTON CANC CTR,PIGMENTED LES CLIN,LEBANON,NH 03756

来源：

MELANOMA RESEARCH | 1995年 / 5卷 / 05期

关键词：

CHEMOTHERAPY; MELANOMA; SURVIVAL; TAMOXIFEN;

D O I：

10.1097/00008390-199510000-00010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic melanoma has a grim prognosis. Response rates and survival of patients treated with combination chemotherapy are not superior to single-agent chemotherapy. This study seeks to evaluate the objective response rate and survival of patients with metastatic melanoma treated with multiagent chemotherapy, with or without tamoxifen, Forty-two patients with metastatic melanoma were treated from March 1982 to February 1988 with dacarbazine, cisplatin and carmustine, with or without tamoxifen, An overall objective response rate of 43% was seen (complete response rate 17%; partial response rate, 26%), The response rate was 54% for patients treated with tamoxifen and 25% for patients treated without tamoxifen, but the results did not achieve statistical significance, Median overall survival was 412 days, and was significantly longer in the tamoxifen-treated group. Combination chemotherapy as described in this study is well-tolerated. The observation that tamoxifen appears to impact on survival should be interpreted with great caution due to the deficiencies in the design of the trial and small patient numbers, A randomized trial of this regimen vs single-agent chemotherapy is indicated and is currently being conducted.

引用

页码：365 / 369

页数：5

共 28 条

[1]

Boring C.C., Squires T.S., Tong T., Et al., Cancer statistics, Ca Cancer J Clin, 43, pp. 7-26, (1993)

[2]

Balch C.M., Houghton A.N., Peters L.J., Cutaneous melanoma, Cancer: Principles and Practice of Oncology, pp. 1612-1661, (1993)

[3]

Papac R.J., Kirkwood J.M., High-dose tamoxifen in metastatic melanoma, Cancer Treat Rep, 67, pp. 1051-1052, (1983)

[4]

Cocconi G., Bella M., Calabresi F., Et al., Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, N Engl J Med, 327, pp. 516-523, (1992)

[5]

McClay E.F., Albright K.D., Jones J.A., Et al., Modulation of cisplatin resistance in human malignant melanoma cells, Cancer Res, 52, pp. 6790-6796, (1992)

[6]

McClay E.F., Albright K.D., Jones J.A., Et al., Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells, Cancer Res, 53, pp. 1571-1576, (1993)

[7]

McClay E.F., Albright K.D., Jones J., Et al., Tamoxifen delays the development of resistance to cisplatin in human malignancies, Proc am Soc Clin Oncol, 132 a, (1993)

[8]

Buzzaid A.C., Murren J.R., Durivage H.J., High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma, Cancer, 68, pp. 1238-1241, (1991)

[9]

Demchak P.A., Mier J.W., Robert N.J., Et al., Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study, J Clin Oncol, 9, pp. 1821-1830, (1991)

[10]

Luger S.M., Kirkwood J.M., Ernstoff M.S., Et al., High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma, J Natl Cancer Inst, 82, pp. 1934-1937, (1990)

← 1 2 3 →